Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Sclerosing Cholangitis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Primary Sclerosing Cholangitis (Gastrointestinal) pipeline landscape.
Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by a progressive course of cholestasis with inflammation and fibrosis of the intrahepatic and extra hepatic bile ducts. Symptoms include abdominal pain, chills, diarrhea, fatigue, itchiness, and weight loss. The predisposing factors include age and inflammatory bowel diseases. Treatment includes antibiotics and bile-acid-binding drugs.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Sclerosing Cholangitis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Sclerosing Cholangitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 13, 6, 2, 11 and 3 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Sclerosing Cholangitis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Primary Sclerosing Cholangitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Primary Sclerosing Cholangitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Primary Sclerosing Cholangitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Primary Sclerosing Cholangitis (Gastrointestinal)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Primary Sclerosing Cholangitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Primary Sclerosing Cholangitis - Overview
Primary Sclerosing Cholangitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Primary Sclerosing Cholangitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Primary Sclerosing Cholangitis - Companies Involved in Therapeutics Development
AbbVie Inc
Albireo Pharma Inc
Avolynt Inc
BiomX Inc
Cadila Healthcare Ltd
Cascade Pharmaceuticals Inc
Chemomab Therapeutics Ltd
CymaBay Therapeutics Inc
Dr. Falk Pharma GmbH
Emergent Biotechnologies LLC
Engitix Ltd
Escient Pharmaceuticals Inc
Gilead Sciences Inc
Hanmi Pharmaceuticals Co Ltd
HighTide Therapeutics Inc
Iltoo Pharma
Immunic Inc
Intercept Pharmaceuticals Inc
LISCure Biosciences Co Ltd
Mirum Pharmaceuticals Inc
NGM Biopharmaceuticals Inc
Orbsen Therapeutics Ltd
Parvus Therapeutics Inc
Pliant Therapeutics Inc
Qing Bile Therapeutics Inc
Scohia Pharma Inc
Sirnaomics Inc
Takeda Pharmaceutical Co Ltd
Yungjin Pharm Co Ltd
Primary Sclerosing Cholangitis - Drug Profiles
A-3907 - Drug Profile
Product Description
Mechanism Of Action
History of Events
aldafermin - Drug Profile
Product Description
Mechanism Of Action
History of Events
aldesleukin - Drug Profile
Product Description
Mechanism Of Action
History of Events
AVO-1681 - Drug Profile
Product Description
Mechanism Of Action
B7-33 - Drug Profile
Product Description
Mechanism Of Action
History of Events
berberine ursodeoxycholate - Drug Profile
Product Description
Mechanism Of Action
History of Events
Biologic for Primary Sclerosing Cholangitis - Drug Profile
Product Description
Mechanism Of Action
History of Events
BX-003 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Cilofexor - Drug Profile
Product Description
Mechanism Of Action
History of Events
CM-101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CS-0159 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Drugs for Gastrointestinal Diseases - Drug Profile
Product Description
Mechanism Of Action
EP-547 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HM-15211 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HTD-1801 - Drug Profile
Product Description
Mechanism Of Action
History of Events
maralixibat chloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
MB-12066 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MORF Beta6-2 - Drug Profile
Product Description
Mechanism Of Action
History of Events
norursodeoxycholic acid - Drug Profile
Product Description
Mechanism Of Action
History of Events
obeticholic acid - Drug Profile
Product Description
Mechanism Of Action
History of Events
odevixibat - Drug Profile
Product Description
Mechanism Of Action
History of Events
PLN-1177 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PLN-1561 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PLN-1705 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PLN-74809 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PVT-201 - Drug Profile
Product Description
Mechanism Of Action
QBT-002 - Drug Profile
Product Description
Mechanism Of Action
QBT-006 - Drug Profile
Product Description
Mechanism Of Action
saroglitazar - Drug Profile
Product Description
Mechanism Of Action
History of Events
SC-435 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SCO-240 - Drug Profile
Product Description
Mechanism Of Action
History of Events
seladelpar lysine - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit NTCP for Infectious Diseases and Unspecified Metabolic Diseases - Drug Profile
Product Description
Mechanism Of Action
Stem Cell Therapy for Gastrointestinal, Infectious and Respiratory Disease - Drug Profile
Product Description
Mechanism Of Action
History of Events
STP-705 - Drug Profile
Product Description
Mechanism Of Action
History of Events
STP-707 - Drug Profile
Product Description
Mechanism Of Action
vidofludimus calcium - Drug Profile
Product Description
Mechanism Of Action
History of Events
volixibat potassium - Drug Profile
Product Description
Mechanism Of Action
History of Events
Primary Sclerosing Cholangitis - Dormant Projects
Primary Sclerosing Cholangitis - Discontinued Products
Primary Sclerosing Cholangitis - Product Development Milestones
Featured News & Press Releases
Feb 22, 2022: HighTide Therapeutics announces end-of-phase 2 meeting with FDA and agreement to Proceed to phase 3 for HTD1801 for the treatment of PSC
Feb 16, 2022: Sirnaomics receives safe to proceed letter for U.S. FDA investigational new drug application for systemic RNAi therapeutic STP707 in primary sclerosing cholangitis (PSC)
Dec 02, 2021: Chemomab announces FDA clearance of its IND application for CM-101, a first-in-class CCL24 neutralizing antibody for the treatment of primary sclerosing cholangitis
Nov 10, 2021: Chemomab announces poster presentation at AASLD's The Liver Meeting 2021
Oct 28, 2021: HighTide Therapeutics to present new PSC and NASH clinical data at AASLD 2021
Jun 24, 2021: Korea-US innovative bio-drug confirms the possibility of treating various rare liver diseases
Jun 23, 2021: Mirum Pharmaceuticals presents analyses from volixibat at the EASL International Liver Congress 2021
Jun 21, 2021: HighTide Therapeutics announces the presentation of topline results of phase 2 study of HTD1801 in PSC patients at the International Liver Congress 2021
Jun 16, 2021: Mirum Pharmaceuticals to showcase analyses from volixibat at The International Liver Congress 2021
Jun 10, 2021: Chemomab announces poster presentation at the International Liver Congress 2021 (EASL)
May 28, 2021: SCOHIA initiates a phase 1 study on an SSTR5 antagonist (SCO-240)
May 18, 2021: BiomX to host key opinion leader event on BX003 for the treatment of inflammatory bowel disease
May 12, 2021: Korea-US LAPS Triple Agonist additionally designated as orphan drug by US FDA
Mar 31, 2021: Immunic and 4SC AG sign agreement regarding the settlement of royalty obligations for Immunic's lead program, IMU-838
Mar 25, 2021: Albireo announces first patients dosed in phase 1 study with new product candidate A3907
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Primary Sclerosing Cholangitis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Primary Sclerosing Cholangitis - Pipeline by AbbVie Inc, 2022
Primary Sclerosing Cholangitis - Pipeline by Albireo Pharma Inc, 2022
Primary Sclerosing Cholangitis - Pipeline by Avolynt Inc, 2022
Primary Sclerosing Cholangitis - Pipeline by BiomX Inc, 2022
Primary Sclerosing Cholangitis - Pipeline by Cadila Healthcare Ltd, 2022
Primary Sclerosing Cholangitis - Pipeline by Cascade Pharmaceuticals Inc, 2022
Primary Sclerosing Cholangitis - Pipeline by Chemomab Therapeutics Ltd, 2022
Primary Sclerosing Cholangitis - Pipeline by CymaBay Therapeutics Inc, 2022
Primary Sclerosing Cholangitis - Pipeline by Dr. Falk Pharma GmbH, 2022
Primary Sclerosing Cholangitis - Pipeline by Emergent Biotechnologies LLC, 2022
Primary Sclerosing Cholangitis - Pipeline by Engitix Ltd, 2022
Primary Sclerosing Cholangitis - Pipeline by Escient Pharmaceuticals Inc, 2022
Primary Sclerosing Cholangitis - Pipeline by Gilead Sciences Inc, 2022
Primary Sclerosing Cholangitis - Pipeline by Hanmi Pharmaceuticals Co Ltd, 2022
Primary Sclerosing Cholangitis - Pipeline by HighTide Therapeutics Inc, 2022
Primary Sclerosing Cholangitis - Pipeline by Iltoo Pharma, 2022
Primary Sclerosing Cholangitis - Pipeline by Immunic Inc, 2022
Primary Sclerosing Cholangitis - Pipeline by Intercept Pharmaceuticals Inc, 2022
Primary Sclerosing Cholangitis - Pipeline by LISCure Biosciences Co Ltd, 2022
Primary Sclerosing Cholangitis - Pipeline by Mirum Pharmaceuticals Inc, 2022
Primary Sclerosing Cholangitis - Pipeline by NGM Biopharmaceuticals Inc, 2022
Primary Sclerosing Cholangitis - Pipeline by Orbsen Therapeutics Ltd, 2022
Primary Sclerosing Cholangitis - Pipeline by Parvus Therapeutics Inc, 2022
Primary Sclerosing Cholangitis - Pipeline by Pliant Therapeutics Inc, 2022
Primary Sclerosing Cholangitis - Pipeline by Qing Bile Therapeutics Inc, 2022
Primary Sclerosing Cholangitis - Pipeline by Scohia Pharma Inc, 2022
Primary Sclerosing Cholangitis - Pipeline by Sirnaomics Inc, 2022
Primary Sclerosing Cholangitis - Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Primary Sclerosing Cholangitis - Pipeline by Yungjin Pharm Co Ltd, 2022
Primary Sclerosing Cholangitis - Dormant Projects, 2022
Primary Sclerosing Cholangitis - Discontinued Products, 2022
List of Figures
Number of Products under Development for Primary Sclerosing Cholangitis, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
